Johnson & Johnson Company Profile (NYSE:JNJ)

About Johnson & Johnson

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: JNJ
  • CUSIP: 47816010
Key Metrics:
  • Previous Close: $113.44
  • 50 Day Moving Average: $118.15
  • 200 Day Moving Average: $117.60
  • 52-Week Range: $2,735,876,000.00 - $94.28
  • Trailing P/E Ratio: 19.93
  • Foreward P/E Ratio: 16.07
  • P/E Growth: 2.73
  • Market Cap: $310.58B
  • Outstanding Shares: 2,735,876,000
  • Beta: 0.62
  • Net Margins: 22.03%
  • Return on Equity: 25.36%
  • Return on Assets: 13.39%
  • Debt-to-Equity Ratio: 0.34%
  • Current Ratio: 3.08%
  • Quick Ratio: 2.68%
Additional Links:
Companies Related to Johnson & Johnson:

Analyst Ratings

Consensus Ratings for Johnson & Johnson (NYSE:JNJ) (?)
Ratings Breakdown: 1 Sell Rating, 11 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $120.32 (6.06% upside)

Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)
DateFirmActionRatingPrice TargetDetails
10/23/2016Societe GeneraleReiterated RatingHold$116.00View Rating Details
10/21/2016ArgusReiterated RatingBuy$145.00View Rating Details
9/19/2016Credit Suisse Group AGReiterated RatingNeutral$123.00View Rating Details
9/13/2016Jefferies GroupLower Price TargetHold$119.00 -> $115.00View Rating Details
9/11/2016Leerink SwannReiterated RatingBuyView Rating Details
9/7/2016BTIG ResearchReiterated RatingNeutralView Rating Details
8/19/2016Deutsche Bank AGReiterated RatingBuy$142.00View Rating Details
7/20/2016RBC Capital MarketsReiterated RatingOutperform$125.00 -> $133.00View Rating Details
7/20/2016BMO Capital MarketsReiterated RatingOutperform$132.00View Rating Details
7/20/2016Royal Bank Of CanadaBoost Price TargetOutperform$125.00 -> $133.00View Rating Details
7/11/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
7/10/2016Barclays PLCReiterated RatingOverweight$120.00 -> $125.00View Rating Details
6/13/2016Goldman Sachs Group Inc.Set Price TargetNeutral$121.00View Rating Details
5/20/2016Raymond James Financial Inc.Reiterated RatingOutperform$120.00View Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00View Rating Details
5/19/2016Bank of America Corp.Reiterated RatingHoldView Rating Details
5/19/2016Morgan StanleyReiterated RatingHoldView Rating Details
4/20/2016Piper Jaffray Cos.Boost Price TargetNeutral$105.00 -> $106.00View Rating Details
4/17/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details
1/27/2016Independent Research GmbHSet Price TargetNeutral$108.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$95.00View Rating Details
10/15/2015S&P Equity ResearchReiterated RatingBuy$120.00View Rating Details
8/25/2015Cowen and CompanyReiterated RatingOutperform$114.00View Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Johnson & Johnson (NYSE:JNJ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/18/2016Q316$1.66$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.40 billionViewListenView Earnings Details
1/20/2015Q414$1.26$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.43$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
Current Year EPS Consensus Estimate: $6.71 EPS
Next Year EPS Consensus Estimate: $7.06 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$1.60$1.67$1.64
Q2 20163$1.64$1.68$1.66
Q3 20162$1.63$1.71$1.67
Q4 20161$1.55$1.55$1.55
Q1 20171$1.67$1.67$1.67
Q2 20171$1.77$1.77$1.77
Q3 20171$1.70$1.70$1.70
Q4 20171$1.86$1.86$1.86
Q1 20181$1.91$1.91$1.91
Q2 20181$2.00$2.00$2.00
(Data provided by Zacks Investment Research)


Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
Annual Dividend:$3.20
Dividend Yield:2.82%
Dividend Growth:7.10% (3 Year Average)
Payout Ratio:56.64% (Based on Trailing 12 Months of Earnings)
47.69% (Based on Current Year Consensus EPS Estimate)
45.33% (Based on Next Year Consensus EPS Estimate)
Track Record:53 Years of Consecutive Dividend Growth

Dividend History for Johnson & Johnson (NYSE:JNJ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Johnson & Johnson (NYSE:JNJ)
Insider Ownership Percentage: 0.11%
Institutional Ownership Percentage: 65.32%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.35View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.05View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.00View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.89View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.20View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.52View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.00View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.60View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.00View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.20View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Johnson & Johnson (NYSE:JNJ)
DateHeadline logoFaith-Based Investor Group Calls for Drugmakers to Be Transparent on Pricing (NYSE:JNJ) - October 24 at 11:04 AM logoJohnson & Johnson: Dark Pool Indicator Flashes Warning (NYSE:JNJ) - October 24 at 11:04 AM
News IconWestwood Management Corp Il Lowers stake in Johnson & Johnson (JNJ) (NYSE:JNJ) - October 23 at 10:06 AM
News IconLeerink Swann Weighs in on Johnson & Johnson's FY2016 Earnings (JNJ) (NYSE:JNJ) - October 23 at 10:06 AM
News IconJohnson & Johnson (JNJ) Raises Dividend to $0.80 Per Share (NYSE:JNJ) - October 23 at 10:06 AM
News IconJohnson & Johnson (JNJ) Stake Boosted by Shell Asset Management Co (NYSE:JNJ) - October 23 at 10:06 AM logoNotable Two Hundred Day Moving Average Cross - JNJ (NYSE:JNJ) - October 21 at 5:49 PM logoHighlights from Johnson & Johnson’s 3Q16 Results (NYSE:JNJ) - October 21 at 5:49 PM logoUS STOCKS-Wall St ends little changed; Microsoft hits record (NYSE:JNJ) - October 21 at 5:49 PM logoMedical Devices Revive JNJ’s Revenue Performance (NYSE:JNJ) - October 21 at 5:49 PM logoA Look at Johnson & Johnson's Segment-Wise Performance in 3Q16 - Market Realist (NYSE:JNJ) - October 21 at 9:06 AM logoJohnson & Johnson Reports Growth in 3Q16 (NYSE:JNJ) - October 21 at 9:06 AM logoJohnson & Johnson’s Growth Rate: How Has It Fluctuated? (NYSE:JNJ) - October 21 at 9:05 AM logoPharma Stock Roundup: Another Strong Quarter from J&J, Lilly Cancer Drug Approved (NYSE:JNJ) - October 21 at 9:05 AM logoThe 3 Biggest Stories From Johnson & Johnson's Third-Quarter Report - Motley Fool (NYSE:JNJ) - October 20 at 6:01 PM logoDependable Johnson & Johnson Needs a Band-Aid - (NYSE:JNJ) - October 20 at 6:01 PM logoJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2016 (NYSE:JNJ) - October 20 at 6:01 PM logoAnother Health Care Chart Looks Sick (NYSE:JNJ) - October 20 at 6:01 PM logoJohnson & Johnson Opens New Global Services Center In Tampa, Florida (NYSE:JNJ) - October 20 at 11:23 AM logoJohnson & Johnson (JNJ) Dropped To Over A 3-Month Low Following Q3 Report (NYSE:JNJ) - October 20 at 11:23 AM
News IconPost Earnings Coverage as Johnson and Johnson Profit Soars 27 Percent (NYSE:JNJ) - October 20 at 11:23 AM logoThe 3 Biggest Stories From Johnson & Johnson's Third-Quarter Report (NYSE:JNJ) - October 20 at 11:23 AM logoJohnson & Johnson: Revisiting After The Pullback (NYSE:JNJ) - October 20 at 11:22 AM logoCan depression be treated like cancer? This startup thinks so (NYSE:JNJ) - October 20 at 9:39 AM logoJohnson & Johnson beat profit and sales expectations, lifts earnings outlook - MarketWatch (NYSE:JNJ) - October 19 at 6:04 PM logoJ&J shares lose ground on fears of Pfizer's answer to Remicade - Reuters (NYSE:JNJ) - October 19 at 6:04 PM logo3 reasons Johnson & Johnson picked Tampa for a global services center (Video) - Tampa Bay Business Journal (NYSE:JNJ) - October 19 at 6:04 PM logoJohnson & Johnson's Robust Pipeline Supports Its Above-Average Valuation (NYSE:JNJ) - October 19 at 1:41 PM logoJohnson & Johnson (JNJ) Is Pulling Back Despite Q3 Report & Guidance Increase (NYSE:JNJ) - October 19 at 10:40 AM
News IconJohnson & Johnson Has Solid 3Q (NYSE:JNJ) - October 19 at 10:40 AM logoJohnson & Johnson Brushes Off Looming Biosimilar Competition, Posts Solid Results (NYSE:JNJ) - October 19 at 10:40 AM
News IconJohnson & Johnson (JNJ) Beats on Q3 Earnings, Revenues (NYSE:JNJ) - October 19 at 10:40 AM logoJohnson & Johnson (JNJ) Q3 2016 Results - Earnings Call Transcript (NYSE:JNJ) - October 19 at 10:40 AM logoS, JNJ and IBM stock couldn't get on board Tuesday's bullish train (NYSE:JNJ) - October 19 at 10:40 AM logoJohnson & Johnson :JNJ-US: Earnings Analysis: Q3, 2016 By the Numbers : October 19, 2016 (NYSE:JNJ) - October 19 at 10:40 AM logo5 Dow Stocks Outperforming Analyst Expectations for 2016 (NYSE:JNJ) - October 19 at 10:40 AM logoJ&J Tops Q3 Views; Could Buoy Intuitive Surgical, Says Evercore - Investor's Business Daily (NYSE:JNJ) - October 18 at 5:41 PM logoJohnson & Johnson (JNJ) 'Tracking Higher Expectations,' CFO Caruso Says - (NYSE:JNJ) - October 18 at 5:41 PM logoPharma Boosts Johnson & Johnson Despite Falling Consumer Sales (NYSE:JNJ) - October 18 at 11:19 AM logoJohnson & Johnson Delivers Another Earnings Beat - Benzinga (NYSE:JNJ) - October 18 at 10:58 AM logoWithout Drugs, Johnson & Johnson Has Nothing (JNJ) - (NYSE:JNJ) - October 18 at 10:58 AM logoWall Street rallies on strong corporate earnings reports (NYSE:JNJ) - October 18 at 10:58 AM logoWhy Visa, Johnson and Johnson, Pfizer, and Two Other Stocks Are in Spotlight Today (NYSE:JNJ) - October 18 at 10:58 AM
News IconJohnson & Johnson Remains Flat Despite Earnings Beat (NYSE:JNJ) - October 18 at 9:58 AM logoJohnson & Johnson Delivers Another Earnings Beat (NYSE:JNJ) - October 18 at 8:43 AM logoJohnson & Johnson Again Buoyed by Pharmaceuticals - Wall Street Journal (NYSE:JNJ) - October 18 at 8:43 AM logoJohnson & Johnson Earnings Top Estimates on Solid Pharmaceutical Sales - (NYSE:JNJ) - October 18 at 7:19 AM logoJohnson & Johnson beat profit and sales expectations, lifts earnings outlook (NYSE:JNJ) - October 18 at 7:19 AM logo3 ETFs to Buy if You Think Johnson & Johnson Will Beat Earnings - (NYSE:JNJ) - October 17 at 5:43 PM logoWhat to Look for in Johnson & Johnson Earnings - 24/7 Wall St. (NYSE:JNJ) - October 17 at 5:43 PM


Johnson & Johnson (NYSE:JNJ) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff